Moricizine

Moricizine

Clinical data
Pregnancy category	B (U.S.)
Pharmacokinetic data
Bioavailability	38%
Protein binding	95%
Elimination half-life	3-4 hours (healthy volunteers), 6-13 hours (cardiac disease)
Identifiers
CAS Number	31883-05-3
PubChem CID	34633
DrugBank	APRD01124
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H25N3O4S
Molar mass	427.518 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Moricizine is a phenothiazine derivative with Vaughan Williams class IC antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34-38 percent, and is 95 percent bound to plasma proteins. Moricizine is extensively metabolized and may have pharmacologically active metabolites. A recent clinical study has shown that moricizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia. Further studies are needed comparing moricizine with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that moricizine is comparable with these agents in the treatment of ventricular tachycardias and fibrillation. Moricizine appears to have a low incidence of serious adverse effects compared with other antiarrhythmics. This combination of apparently similar efficacy with a decreased incidence of adverse effects makes moricizine a worthwhile addition to currently available antiarrhythmic agents.

External links

• Moricizine
• Template:MedlinePlusDrugInfo

Template:Antiarrhythmic agents

Template:WikiDoc Sources